GlassScriptPhysician profile
Andrea A Dameron
NPI 1689878795
$1,223.36
in general payments reported to CMS, 2019-2025
13 companies · $183 in 2025
The $183 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $202 · 2022: $113 · 2023: $366 · 2024: $359 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $908.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $908.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $320.63 | 2021-2025 | Lynparza, Keytruda, Keytruda Qlex |
| Glaxosmithkline, LLC. | $245.38 | 2021-2025 | Jemperli, Zejula |
| Myriad Genetic Laboratories, INC. | $172.22 | 2021-2024 | Myrisk, Precisetumor |
| Astrazeneca Pharmaceuticals LP | $167.53 | 2022-2025 | Lynparza |
| Eisai INC. | $68.60 | 2021-2025 | |
| Coherus Oncology, INC. | $60.29 | 2021-2024 | |
| Pfizer INC. | $38.21 | 2024 | |
| Ethicon US, LLC | $32.03 | 2021-2023 | Evarrest |
| Abbvie INC. | $30.92 | 2023-2024 | |
| Astellas Pharma US INC | $26.30 | 2023 | Veozah |
| Seagen INC. | $25.67 | 2023 | Tivdak |
| Immunogen, INC. | $22.71 | 2023 | Elahere |
| Molnlycke Health Care US, LLC | $12.87 | 2025 | Mepilex Border Post-Op Ag |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Dameron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.